Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Urinary Incontinence - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2017, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape. Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively. Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones). - The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Urinary Incontinence - Overview Urinary Incontinence - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Urinary Incontinence - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Urinary Incontinence - Companies Involved in Therapeutics Development Astellas Pharma Inc Beech Tree Labs Inc Celogos SA Crystec Ltd FemmePharma Global Healthcare Inc GTx Inc Innovacell Biotechnologie AG Ipsen SA Pfizer Inc Taiho Pharmaceutical Co Ltd Takeda Pharmaceutical Company Ltd Urinary Incontinence - Drug Profiles (mirabegron + solifenacin succinate) - Drug Profile Product Description Mechanism Of Action R&D Progress abobotulinumtoxinA - Drug Profile Product Description Mechanism Of Action R&D Progress BTL-hs - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Ischemic Heart Failure, Gastrointestinal Disorders and Urological Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Cell Therapy for Urinary Incontinence - Drug Profile Product Description Mechanism Of Action R&D Progress enobosarm - Drug Profile Product Description Mechanism Of Action R&D Progress Gtx-027 - Drug Profile Product Description Mechanism Of Action R&D Progress ICES-13 - Drug Profile Product Description Mechanism Of Action R&D Progress litoxetine - Drug Profile Product Description Mechanism Of Action R&D Progress OP-233 - Drug Profile Product Description Mechanism Of Action R&D Progress oxybutynin chloride - Drug Profile Product Description Mechanism Of Action R&D Progress Prof-003 - Drug Profile Product Description Mechanism Of Action R&D Progress RCD-1 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize 5-HT2C for Urinary Incontinence - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit NET for Stress Urinary Incontinence - Drug Profile Product Description Mechanism Of Action R&D Progress TAS-303 - Drug Profile Product Description Mechanism Of Action R&D Progress tolterodine - Drug Profile Product Description Mechanism Of Action R&D Progress Urinary Incontinence - Dormant Projects Urinary Incontinence - Discontinued Products Urinary Incontinence - Product Development Milestones Featured News & Press Releases Jun 12, 2017: GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence May 11, 2017: GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-024 (enobosarm) on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting Feb 24, 2016: GTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx-027 on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting Jan 13, 2016: GTx Announces Initiation of Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence Oct 13, 2015: GTx Receives FDA Clearance to Initiate Clinical Trial in Stress Urinary Incontinence May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg Nov 06, 2012: Beech Tree Labs Completes Phase IIa Urinary Incontinence Clinical Trial Using UISH001 Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency Aug 30, 2011: Innovacell passes a further milestone Apr 13, 2011: Beech Tree Labs Initiates Urinary Incontinence Trial Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Urinary Incontinence, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Urinary Incontinence - Pipeline by Astellas Pharma Inc, H2 2017 Urinary Incontinence - Pipeline by Beech Tree Labs Inc, H2 2017 Urinary Incontinence - Pipeline by Celogos SA, H2 2017 Urinary Incontinence - Pipeline by Crystec Ltd, H2 2017 Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H2 2017 Urinary Incontinence - Pipeline by GTx Inc, H2 2017 Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2017 Urinary Incontinence - Pipeline by Ipsen SA, H2 2017 Urinary Incontinence - Pipeline by Pfizer Inc, H2 2017 Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 Urinary Incontinence - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Urinary Incontinence - Dormant Projects, H2 2017 Urinary Incontinence - Dormant Projects, H2 2017 (Contd..1), H2 2017 Urinary Incontinence - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
